Basic Information


GTO ID GTC0144
Trial ID NCT01583686
Disease Ovarian Cancer | Lung Cancer | Mesothelioma | Pancreatic Cancer | Cervical Cancer
Altered gene MESO
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment MESO CAR-T cells
PhasePhase1|Phase2
Recruitment statusTerminated
TitleCAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Year2012
CountryUnited States
Company sponsorNational Cancer Institute (NCI)
Other ID(s)120111|12-C-0111
Vector information
Vectorretrovirus

Clinical Result

Cohort1: dose level 1
Administration route intravenous infusion
Dosage 1E6 cells
Donor type Autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 3/3(PD)
Adverse reactions 1/3(Gastrointestinal disorders)
Cohort2: dose level 2
Administration route intravenous infusion
Dosage 3E6 cells
Donor type Autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 1/3(SD); 2/3(PD)
Adverse reactions 2/3(Respiratory, thoracic and mediastinal disorders; Platelet count decreased)
Cohort3: dose level 3
Administration route intravenous infusion
Dosage 1E7 cells
Donor type Autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 3/3(PD)
Adverse reactions no any CAR-T-related severe events
Cohort4: dose level 4
Administration route intravenous infusion
Dosage 3E7 cells
Donor type Autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 3/3(PD)
Adverse reactions 1/3(Lymphocyte count decreased)
Cohort5: dose level 5
Administration route intravenous infusion
Dosage 1E8 cells
Donor type Autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 3/3(PD)
Adverse reactions 1/3(All-cause mortality); 2/3(Blood and lymphatic system disorders; Lymphocyte count decreased)

Relationship Graph

Overview of Knowledge Graph